Skip to main content
Signal8

Abpro Holdings, Inc. (ABPO)

Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Abpro Holdings, Inc. logo

Abpro Holdings, Inc.

OTC:ABPOOTC (delisted from Nasdaq, Form 25 effective Oct 10, 2026)Healthcare
AH+0.00%$0.5337
Close$0.5337+0.70%
Mkt Cap$3.15M
EV-
Float5.01M
O/S5.9M
VOL23K sh
$ Vol$12K
RVOL1.36×
Inst Own0.3%
SI0.3%
Net Cash/Sh-
Dilution
Abpro Holdings, Inc. logoOTC:ABPOAH$0.5337+0.00%
FormDescription
NT 10-Q
SEC Filing
25-NSE
SEC Filing
8-K
8-K
10-Q
13G/A
Beneficial Ownership Report (Amended)
8-K
10-Q
NT 10-Q
NOTIFICATION OF LATE FILING
10-K/A
AMENDMENT NO. 1 TO FORM 10-K
10-K
ANNUAL REPORT
NT 10-K
NOTIFICATION OF LATE FILING
8-K
CURRENT REPORT
8-K
CURRENT REPORT
13G
Beneficial Ownership Report
8-K
CURRENT REPORT
8-K
CURRENT REPORT
8-K
CURRENT REPORT
8-K
CURRENT REPORT
8-K
CURRENT REPORT
EFFECT
Notice of Effectiveness
CORRESP
SEC Filing
S-1/A
AMENDMENT NO. 1 TO FORM S-1
424B3
PROSPECTUS SUPPLEMENT
10-Q
QUARTERLY REPORT

1-25 of 254

…
    Abpro Holdings, Inc. (ABPO) SEC Filings: 10-K, 10-Q, 8-K | Signal8